Skip to main content
Erschienen in: Pediatric Nephrology 3/2021

25.06.2020 | Clinical Quiz

An 8-month-old infant with hypercalcemia and hyperphosphatemia—Answers

verfasst von: Oğuz Özler, Gül Yeşiltepe Mutlu, Mehmet Taşdemir, Şahin Avcı, Ilmay Bilge, Şükrü Hatun

Erschienen in: Pediatric Nephrology | Ausgabe 3/2021

Einloggen, um Zugang zu erhalten

Excerpt

Hyperphosphatemia in children is caused by several different etiologies including kidney failure, vitamin D toxicity, tumor lysis syndrome, tissue necrosis, and endocrine disorders including hypoparathyroidism, pseudohypoparathyroidism, secondary hyperparathyroidism, diabetic ketoacidosis (DKA), and severe hyperglycemia [1]. The principal causes of hyperphosphatemia are low levels of parathyroid hormone (PTH), decreased renal response to PTH, transcellular shifts from intracellular to extracellular spaces (DKA, lactic acidosis, severe hyperglycemia, crush injury, rhabdomyolysis or tumor lysis syndrome), increased intake of phosphate (rectal enema or intravenous replacement), and increased absorption (vitamin D toxicity) [2]. In our case, the levels of PTH, blood glucose, and arterial blood gas analysis were normal. There was also no previous history of malignancy, injury, or excessive use of vitamin D. Since there was no evidence for other differentials, and our patient also had a moderately decreased eGFR due to posterior urethral valve (PUV) and renal dysplasia, the high phosphate level was considered to be related with chronic kidney disease (CKD). In addition to this high phosphate level, a high calcium level was also observed in these patients because of higher levels of the parathyroid hormone [3]. However, since PTH level was normal in our patient, hypercalcemia was not considered to be related with kidney disease. The blood calcium levels of the parents were investigated and found to be normal. In addition, since urinary calcium excretion was also normal, genetic analysis for CaSR mutation was planned. Given a history of craniosynostosis and right posterior plagiocephaly along with hypercalcemia and hyperphosphatemia, the levels of serum PTH, 25(OH) vitamin D, 1.25(OH) vitamin D, and thyroid hormones were tested in order to rule out hyperparathyroidism, vitamin D intoxication, and thyroid diseases, the results of which fell within normal ranges. However, the serum alkaline phosphatase (ALP) level was found to be low (36 IU/L (N 83-469)), indicating the possibility of various disorders including hypophosphatasia, osteogenesis imperfecta, malignancies, surgeries, traumas, starvation, and nutrient deficiencies [4]. …
Literatur
1.
Zurück zum Zitat Leung J, Crook M (2019) Disorders of phosphate metabolism. J Clin Pathol 72:741–747CrossRef Leung J, Crook M (2019) Disorders of phosphate metabolism. J Clin Pathol 72:741–747CrossRef
2.
Zurück zum Zitat Carfagna F, Del Vecchio L, Pontoriero G, Locatelli F (2018) Current and potential treatment options for hyperphosphatemia. Expert Opin Drug Saf 17:597–607CrossRef Carfagna F, Del Vecchio L, Pontoriero G, Locatelli F (2018) Current and potential treatment options for hyperphosphatemia. Expert Opin Drug Saf 17:597–607CrossRef
7.
Zurück zum Zitat Whyte MP, Greenberg CR, Salman NJ, Bober MB, McAlister WH, Wenkert D, Van Sickle BJ, Simmons JH, Edgar TS, Bauer ML, Hamdan MA, Bishop N, Lutz RE, McGinn M, Craig S, Moore JN, Taylor JW, Cleveland RH, Cranley WR, Lim R, Thacher TD, Mayhew JE, Downs M, Millán JL, Skrinar AM, Crine P, Landy H (2012) Enzyme-replacement therapy in life-threatening hypophosphatasia. N Engl J Med 366:904–913. https://doi.org/10.1056/NEJMoa1106173 Whyte MP, Greenberg CR, Salman NJ, Bober MB, McAlister WH, Wenkert D, Van Sickle BJ, Simmons JH, Edgar TS, Bauer ML, Hamdan MA, Bishop N, Lutz RE, McGinn M, Craig S, Moore JN, Taylor JW, Cleveland RH, Cranley WR, Lim R, Thacher TD, Mayhew JE, Downs M, Millán JL, Skrinar AM, Crine P, Landy H (2012) Enzyme-replacement therapy in life-threatening hypophosphatasia. N Engl J Med 366:904–913. https://​doi.​org/​10.​1056/​NEJMoa1106173
8.
Zurück zum Zitat Whyte MP, Simmons JH, Moseley S, Fujita KP, Bishop N, Salman NJ, Taylor J, Phillips D, McGinn M, McAlister WH (2019) Asfotase alfa for infants and young children with hypophosphatasia: 7 year outcomes of a single-arm, open-label, phase 2 extension trial. Lancet Diabetes Endocrinol 7:93–105. https://doi.org/10.1016/S2213-8587(18)30307-3 Whyte MP, Simmons JH, Moseley S, Fujita KP, Bishop N, Salman NJ, Taylor J, Phillips D, McGinn M, McAlister WH (2019) Asfotase alfa for infants and young children with hypophosphatasia: 7 year outcomes of a single-arm, open-label, phase 2 extension trial. Lancet Diabetes Endocrinol 7:93–105. https://​doi.​org/​10.​1016/​S2213-8587(18)30307-3
9.
11.
Zurück zum Zitat Whyte MP, Zhang F, Wenkert D, McAlister WH, Mack KE, Benigno MC, Coburn SP, Wagy S, Griffin DM, Ericson KL, Mumm S (2015) Hypophosphatasia: validation and expansion of the clinical nosology for children from 25years experience with 173 pediatric patients. Bone 75:229–239. https://doi.org/10.1016/j.bone.2015.02.022 Whyte MP, Zhang F, Wenkert D, McAlister WH, Mack KE, Benigno MC, Coburn SP, Wagy S, Griffin DM, Ericson KL, Mumm S (2015) Hypophosphatasia: validation and expansion of the clinical nosology for children from 25years experience with 173 pediatric patients. Bone 75:229–239. https://​doi.​org/​10.​1016/​j.​bone.​2015.​02.​022
Metadaten
Titel
An 8-month-old infant with hypercalcemia and hyperphosphatemia—Answers
verfasst von
Oğuz Özler
Gül Yeşiltepe Mutlu
Mehmet Taşdemir
Şahin Avcı
Ilmay Bilge
Şükrü Hatun
Publikationsdatum
25.06.2020
Verlag
Springer Berlin Heidelberg
Erschienen in
Pediatric Nephrology / Ausgabe 3/2021
Print ISSN: 0931-041X
Elektronische ISSN: 1432-198X
DOI
https://doi.org/10.1007/s00467-020-04666-5

Weitere Artikel der Ausgabe 3/2021

Pediatric Nephrology 3/2021 Zur Ausgabe

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.